Cancer-Focused Genetic Testing Services Market Outlook (2022 to 2032)
The global cancer-focused genetic testing services market is estimated at US$ 6.5 Billion in 2021 and is expected to secure US$ 7.15 Billion by 2022. The market is projected to procure USD 18.55 Billion by 2032 while expanding at a CAGR of 10% during the forecast period from 2022 to 2032.
The global cancer-focused genetic testing services are expected to exhibit positive growth owing to the increasing number of people suffering from cancer. Moreover, the increasing prevalence of breast cancer and lung cancer is fuelling the growth of the market.
Attributes
Details
Global Cancer-Focused Genetic Testing Services Market CAGR (2022 to 2032)
10%
Global Cancer-Focused Genetic Testing Services Market (2032)
US$ 18.55 Billion
Global Cancer-Focused Genetic Testing Services Market Attraction
Increasing awareness regarding cancer prevention along with tech-savvy diagnostics facilities are augmenting the growth of the global cancer-focused genetic testing services market.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
What are the Key Factors Propelling the Cancer-Focused Genetic Testing Services?
The rising prevalence of cancer across different age groups is the primary factor driving the growth of the cancer-focused genetic testing services market over the forecast period. The change in the lifestyle of people along with increasing levels of stress is responsible for the increasing prevalence of cancer which will ultimately upsurge the growth of the cancer-focused genetic testing services market.
Cancer-Focused Genetic Testing is always performed under the supervision of a genetic specialist. To perform the genetic testing, a blood sample is taken to perform the panel test and diagnose the mutation in the gene. There are two groups of people who require to perform Cancer-Focused Genetic Testing.
Group one people include patient who does not have cancer but some of their family members have a history of cancer. Group two includes patients who already have cancer and want to know whether cancer can occur due to genetic mutation.
Increasing awareness among the people about personal health along with the launch of various awareness campaigns by different NGOs has propelled the growth of the cancer-focused genetic testing services market. In addition, the availability of various easy methods for cancer-focused genetic testing is expected to increase the demand for the cancer-focused genetic testing services market over the next decade.
What are the Major Trends in the Global Cancer-Focused Genetic Testing Services?
The change in lifestyle, consumption of unhealthy food along with more people being diagnosed with mental and physical health problems are increasing the incidences of cancer. This, in turn, is responsible for the exponential growth of the cancer-focused genetic testing services market over the forecast period.
In general, cancer-focused genetic testing can be done by two methods i.e. chromosome testing and DNA testing. Chromosome testing is done to analyze the single mutation while DNA testing is done to analyze the multiple mutations in the gene. Furthermore, DNA testing can be done by two methods i.e., direct DNA testing and indirect DNA testing. Cancer-Focused Genetic Testing is the most common way to diagnose breast cancer and colorectal cancer. Among all service providers in the cancer-focused genetic testing services market, the diagnostic laboratories segment is expected to dominate the market share in terms of value.
Find your sweet spots for generating winning opportunities in this market.
What Challenges are in Store for Cancer-Focused Genetic Testing Services?
In comparison to people suffering from cancer due to other reasons, very few people suffer from cancer due to genetic mutation which can deter the growth of the cancer-focused genetic testing services market. Also, less preference of people in developing economies toward genetic testing will also hamper the growth of the Cancer-Focused Genetic Testing Services market.
Only 5-10% of cancer cases are related to genetics which may decline the importance of Cancer-Focused Genetic Testing Services. Lack of awareness regarding cancer prevention and treatment especially in underdeveloped regions like South Africa is hampering the growth of the overall market.
What is the Segmental Analysis for the Global Cancer-Focused Genetic Testing Services?
Breast Cancer Augmenting Demand for Cancer-Focused Genetic Testing Services?
Cancer Awareness Creating Opportunities for Cancer-Focused Genetic Testing Services
By cancer type, the cancer-focused genetic testing services are segmented into breast cancer, colorectal cancer, lung cancer, bladder cancer, kidney cancer, and other cancer types. The American Cancer Society states that 5% to 10% of breast cancer is hereditary. The reoccurrence or return of the first cancer too is playing a key role in the increasing cases of breast cancer in women.
As more women are becoming aware of the same, they are referring to getting tested regularly. Thus, mammograms are widely used for checking breast cancer. This, in turn, is increasing the use of cancer-focused genetic testing services. Owing to these reasons, breast cancer is expected to hold a 40% market share in the cancer-focused genetic testing services market.
The Convenience of Testing Increasing the Popularity of Diagnostic Laboratories?
Multiple Testing Service Driving Growth of Diagnostic Laboratories
By service type Cancer-Focused Genetic Testing Services are segmented into hospitality, specialty clinics, diagnostic laboratories, specialized cancer institutes
Diagnostic laboratories are expected to hold the largest share of the cancer-focused genetic testing services market. This is owing to the multi-faceted usage of these labs. Diagnostic labs offer multiple tests under one roof. Thus, it becomes easier for testing blood, tumors, and tissues. The increasing awareness regarding the prevention of cancer is increasing the dependency on cancer-focused genetic testing services. Thus, diagnostic laboratories are expected to hold more than 45% market share for cancer-focused genetic testing services in the assessment period 2022 to 2032.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
What is the Regional Analysis of the Global Cancer-Focused Genetic Testing Services?
How is the Growth of Cancer-Focused Genetic Testing Services Unfolding in the USA?
Breast Cancer Accelerating Demand for Cancer-Focused Genetic Testing Services
American Cancer Society states that 1 in three women is diagnosed with breast cancer every year in the USA Nearly 30% of women living in the USA are suffering from breast cancer. Most middle-aged and elderly women suffer from cancer in the country. This, in turn, is increasing the demand for cancer-focused testing services.
Most women have exhibited a preference for getting tested for breast cancer on a regular basis. This is to avoid the complications caused by cancer in the longer run. As an early diagnosis of cancer helps in early treatment and medication, cancer-focused genetic testing services are gaining prominence. Furthermore, the government of the region along with NGOs and cancer awareness programs is taking steps to spread the importance of cancer testing. Thus, owing to the factors mentioned above, the USA is expected to register a CAGR of 10% for cancer-focused genetic testing services.
Government Initiatives Escalating Demand for Cancer-Focused Genetic Testing Services in China?
Lung Cancer Boosting the Demand for Cancer-Focused Genetic Testing Services
The rate of people suffering from lung cancer has exponentially grown in China. Tobacco smoke exposure is playing a key role in the increasing number of cases of lung cancer in the country. Journal of Thoracic Oncology states that lung cancer accounts for 20% of all cancer diagnoses. This, in turn, is increasing the demand for cancer-focused genetic testing services in the region.
The government of the country is focusing on implementing strategies to develop systematic programs for cancer prevention and detection. With the increasing population of the country, the chances of people being diagnosed with cancer have increased with time. Furthermore, most people have shown an inclination toward getting tested regularly. This, in turn, is increasing the dependency on cancer-focused genetic testing services. Thus, due to the aforementioned factors, China is expected to register a CAGR of nearly 12% for cancer-focused genetic testing services in the assessment period 2022 to 2032.
What is the Intensity of the Competition in the Global Cancer-Focused Genetic Testing Services?
Key players in the global cancer-focused genetic testing services market are Cleveland Clinic, Fortis Healthcare, KIMS Hospitals, Rush University Medical Center, The Johns Hopkins Hospital, Bridgeport Hospital, Greenwich Hospital, Lawrence Memorial Hospital, Westerly Hospital, Yale New Haven Hospital, Northeast Medical Group, and others.
Some of the recent developments in the global cancer-focused genetic testing services market are as follows:
In November 2021, Cleveland Clinic expanded its cancer genomic testing services in collaboration with three different entities. The healthcare sector is focusing on providing individualized treatment plans based on their unique genomic profile.
The Johns Hopkins Hospital, a key player in the cancer-focused genetic testing services market is focusing on using advanced technological features to upscale genetic testing services for cancer patients.
Report Scope
Report Attribute
Details
Growth Rate
CAGR of 10% from 2022 to 2032
Market Value for 2022
US$ 7.15 Billion
Market Value for 2032
US$ 18.55 Billion
Base Year for Estimation
2021
Historical Data
2017 to 2021
Forecast Period
2022 to 2032
Quantitative Units
USD Billion for Value
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Test Type
Cancer Type
Service Provider
Region
Regions Covered
North America
Latin America
Europe
Asia Pacific
Middle East & Africa
Key Countries Profiled
USA
Canada
Brazil
Mexico
Germany
United Kingdom
France
Spain
Italy
China
Japan
South Korea
Malaysia
Singapore
Australia
GCC Countries
South Africa
Israel
Key Companies Profiled
Cleveland Clinic
Fortis Healthcare
KIMS Hospitals
Rush University Medical Center
The Johns Hopkins Hospital
Bridgeport Hospital
Greenwich Hospital
Lawrence Memorial Hospital
Westerly Hospital
Yale New Haven Hospital
Northeast Medical Group
Report Customization & Pricing
Available upon Request
Key Segments Covered in the Cancer-Focused Genetic Testing Services
By Test Type:
Chromosome
DNA
Direct DNA Testing
Indirect DNA Testing
Biochemical
By Cancer Type:
Breast Cancer
Colorectal Cancer
Lung Cancer
Bladder Cancer
Kidney Cancer
Other Cancer
By Service Provider:
Hospitals
Specialty Clinics
Diagnostic Laboratories
Specialized Cancer Institutes
By Region:
North America
Latin America
Europe
Asia Pacific
Middle East & Africa
Frequently Asked Questions
At what rate is the global cancer-focused genetic testing services market expected to grow?
The global cancer-focused genetic testing services market is expected to register a CAGR of 10% in the assessment period.
Which region is projected to garner maximum market share?
The USA is expected to register a CAGR of 10% during the forecast period.
Who are the key participants of the global cancer-focused genetic testing services market?
Cleveland Clinic, Fortis Healthcare, KIMS Hospitals, Rush University Medical Center, and The Johns Hopkins Hospital are some prominent cancer-focused genetic testing service providers
Table of Content
1. Executive Summary | Cancer-Focused Genetic Testing Services Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032
4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021
4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Test Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Test Type, 2017 to 2021
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Test Type, 2022 to 2032
5.3.1. Chromosome Testing
5.3.2. DNA Testing
5.3.3. Direct DNA Testing
5.3.4. Indirect DNA Testing
5.3.5. Biochemical Genetic Testing
5.4. Y-o-Y Growth Trend Analysis By Test Type, 2017 to 2021
5.5. Absolute $ Opportunity Analysis By Test Type, 2022 to 2032
6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Cancer Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Cancer Type, 2017 to 2021
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Cancer Type, 2022 to 2032
6.3.1. Breast Cancer
6.3.2. Colorectal Cancer
6.3.3. Lung Cancer
6.3.4. Bladder Cancer
6.3.5. Kidney Cancer
6.3.6. Other Cancer Types
6.4. Y-o-Y Growth Trend Analysis By Cancer Type, 2017 to 2021
6.5. Absolute $ Opportunity Analysis By Cancer Type, 2022 to 2032
7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Service Provider
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Service Provider, 2017 to 2021
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Service Provider, 2022 to 2032
7.3.1. Hospital
7.3.2. Specialty Clinics
7.3.3. Diagnostic Laboratories
7.3.4. Specialized Cancer Institutes
7.4. Y-o-Y Growth Trend Analysis By Service Provider, 2017 to 2021
7.5. Absolute $ Opportunity Analysis By Service Provider, 2022 to 2032
8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa(MEA)
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
9.2.1. By Country
9.2.1.1. United Kingdom
9.2.1.2. Canada
9.2.2. By Test Type
9.2.3. By Cancer Type
9.2.4. By Service Provider
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Test Type
9.3.3. By Cancer Type
9.3.4. By Service Provider
9.4. Key Takeaways
10. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Test Type
10.2.3. By Cancer Type
10.2.4. By Service Provider
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Test Type
10.3.3. By Cancer Type
10.3.4. By Service Provider
10.4. Key Takeaways
11. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Test Type
11.2.3. By Cancer Type
11.2.4. By Service Provider
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Test Type
11.3.3. By Cancer Type
11.3.4. By Service Provider
11.4. Key Takeaways
12. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. Malaysia
12.2.1.5. Singapore
12.2.1.6. Australia
12.2.1.7. Rest of Asia Pacific
12.2.2. By Test Type
12.2.3. By Cancer Type
12.2.4. By Service Provider
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Test Type
12.3.3. By Cancer Type
12.3.4. By Service Provider
12.4. Key Takeaways
13. MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of Middle East and Africa(MEA)
13.2.2. By Test Type
13.2.3. By Cancer Type
13.2.4. By Service Provider
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Test Type
13.3.3. By Cancer Type
13.3.4. By Service Provider
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. United Kingdom
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2021
14.1.2.1. By Test Type
14.1.2.2. By Cancer Type
14.1.2.3. By Service Provider
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2021
14.2.2.1. By Test Type
14.2.2.2. By Cancer Type
14.2.2.3. By Service Provider
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2021
14.3.2.1. By Test Type
14.3.2.2. By Cancer Type
14.3.2.3. By Service Provider
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2021
14.4.2.1. By Test Type
14.4.2.2. By Cancer Type
14.4.2.3. By Service Provider
14.5. Rest of Latin America
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2021
14.5.2.1. By Test Type
14.5.2.2. By Cancer Type
14.5.2.3. By Service Provider
14.6. Germany
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2021
14.6.2.1. By Test Type
14.6.2.2. By Cancer Type
14.6.2.3. By Service Provider
14.7. United Kingdom
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2021
14.7.2.1. By Test Type
14.7.2.2. By Cancer Type
14.7.2.3. By Service Provider
14.8. France
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2021
14.8.2.1. By Test Type
14.8.2.2. By Cancer Type
14.8.2.3. By Service Provider
14.9. Spain
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2021
14.9.2.1. By Test Type
14.9.2.2. By Cancer Type
14.9.2.3. By Service Provider
14.10. Italy
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2021
14.10.2.1. By Test Type
14.10.2.2. By Cancer Type
14.10.2.3. By Service Provider
14.11. Rest of Europe
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2021
14.11.2.1. By Test Type
14.11.2.2. By Cancer Type
14.11.2.3. By Service Provider
14.12. China
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2021
14.12.2.1. By Test Type
14.12.2.2. By Cancer Type
14.12.2.3. By Service Provider
14.13. Japan
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2021
14.13.2.1. By Test Type
14.13.2.2. By Cancer Type
14.13.2.3. By Service Provider
14.14. South Korea
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2021
14.14.2.1. By Test Type
14.14.2.2. By Cancer Type
14.14.2.3. By Service Provider
14.15. Malaysia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2021
14.15.2.1. By Test Type
14.15.2.2. By Cancer Type
14.15.2.3. By Service Provider
14.16. Singapore
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2021
14.16.2.1. By Test Type
14.16.2.2. By Cancer Type
14.16.2.3. By Service Provider
14.17. Australia
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2021
14.17.2.1. By Test Type
14.17.2.2. By Cancer Type
14.17.2.3. By Service Provider
14.18. Rest of Asia Pacific
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2021
14.18.2.1. By Test Type
14.18.2.2. By Cancer Type
14.18.2.3. By Service Provider
14.19. GCC Countries
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2021
14.19.2.1. By Test Type
14.19.2.2. By Cancer Type
14.19.2.3. By Service Provider
14.20. South Africa
14.20.1. Pricing Analysis
14.20.2. Market Share Analysis, 2021
14.20.2.1. By Test Type
14.20.2.2. By Cancer Type
14.20.2.3. By Service Provider
14.21. Israel
14.21.1. Pricing Analysis
14.21.2. Market Share Analysis, 2021
14.21.2.1. By Test Type
14.21.2.2. By Cancer Type
14.21.2.3. By Service Provider
14.22. Rest of the Middle East and Africa(MEA)
14.22.1. Pricing Analysis
14.22.2. Market Share Analysis, 2021
14.22.2.1. By Test Type
14.22.2.2. By Cancer Type
14.22.2.3. By Service Provider
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Test Type
15.3.3. By Cancer Type
15.3.4. By Service Provider
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Cleveland Clinic
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Fortis Healthcare
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. KIMS Hospitals
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Rush University Medical Center
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. The Johns Hopkins Hospital
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Bridgeport Hospital
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Greenwich Hospital
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Lawrence Memorial Hospital
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Westerly Hospital
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. Yale New Haven Hospital
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
16.1.11. Northeast Medical Group
16.1.11.1. Overview
16.1.11.2. Product Portfolio
16.1.11.3. Profitability by Market Segments
16.1.11.4. Sales Footprint
16.1.11.5. Strategy Overview
16.1.11.5.1. Marketing Strategy
17. Assumptions & Acronyms Used18. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2017 to 2032
Table 2: Global Market Value (US$ Million) Forecast by Test Type, 2017 to 2032
Table 3: Global Market Value (US$ Million) Forecast by Cancer Type, 2017 to 2032
Table 4: Global Market Value (US$ Million) Forecast by Service Provider, 2017 to 2032
Table 5: North America Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 6: North America Market Value (US$ Million) Forecast by Test Type, 2017 to 2032
Table 7: North America Market Value (US$ Million) Forecast by Cancer Type, 2017 to 2032
Table 8: North America Market Value (US$ Million) Forecast by Service Provider, 2017 to 2032
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 10: Latin America Market Value (US$ Million) Forecast by Test Type, 2017 to 2032
Table 11: Latin America Market Value (US$ Million) Forecast by Cancer Type, 2017 to 2032
Table 12: Latin America Market Value (US$ Million) Forecast by Service Provider, 2017 to 2032
Table 13: Europe Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 14: Europe Market Value (US$ Million) Forecast by Test Type, 2017 to 2032
Table 15: Europe Market Value (US$ Million) Forecast by Cancer Type, 2017 to 2032
Table 16: Europe Market Value (US$ Million) Forecast by Service Provider, 2017 to 2032
Table 17: Asia Pacific Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 18: Asia Pacific Market Value (US$ Million) Forecast by Test Type, 2017 to 2032
Table 19: Asia Pacific Market Value (US$ Million) Forecast by Cancer Type, 2017 to 2032
Table 20: Asia Pacific Market Value (US$ Million) Forecast by Service Provider, 2017 to 2032
Table 21: MEA Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 22: MEA Market Value (US$ Million) Forecast by Test Type, 2017 to 2032
Table 23: MEA Market Value (US$ Million) Forecast by Cancer Type, 2017 to 2032
Table 24: MEA Market Value (US$ Million) Forecast by Service Provider, 2017 to 2032
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Test Type, 2022 to 2032
Figure 2: Global Market Value (US$ Million) by Cancer Type, 2022 to 2032
Figure 3: Global Market Value (US$ Million) by Service Provider, 2022 to 2032
Figure 4: Global Market Value (US$ Million) by Region, 2022 to 2032
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2017 to 2032
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2022 to 2032
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2022 to 2032
Figure 8: Global Market Value (US$ Million) Analysis by Test Type, 2017 to 2032
Figure 9: Global Market Value Share (%) and BPS Analysis by Test Type, 2022 to 2032
Figure 10: Global Market Y-o-Y Growth (%) Projections by Test Type, 2022 to 2032
Figure 11: Global Market Value (US$ Million) Analysis by Cancer Type, 2017 to 2032
Figure 12: Global Market Value Share (%) and BPS Analysis by Cancer Type, 2022 to 2032
Figure 13: Global Market Y-o-Y Growth (%) Projections by Cancer Type, 2022 to 2032
Figure 14: Global Market Value (US$ Million) Analysis by Service Provider, 2017 to 2032
Figure 15: Global Market Value Share (%) and BPS Analysis by Service Provider, 2022 to 2032
Figure 16: Global Market Y-o-Y Growth (%) Projections by Service Provider, 2022 to 2032
Figure 17: Global Market Attractiveness by Test Type, 2022 to 2032
Figure 18: Global Market Attractiveness by Cancer Type, 2022 to 2032
Figure 19: Global Market Attractiveness by Service Provider, 2022 to 2032
Figure 20: Global Market Attractiveness by Region, 2022 to 2032
Figure 21: North America Market Value (US$ Million) by Test Type, 2022 to 2032
Figure 22: North America Market Value (US$ Million) by Cancer Type, 2022 to 2032
Figure 23: North America Market Value (US$ Million) by Service Provider, 2022 to 2032
Figure 24: North America Market Value (US$ Million) by Country, 2022 to 2032
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 28: North America Market Value (US$ Million) Analysis by Test Type, 2017 to 2032
Figure 29: North America Market Value Share (%) and BPS Analysis by Test Type, 2022 to 2032
Figure 30: North America Market Y-o-Y Growth (%) Projections by Test Type, 2022 to 2032
Figure 31: North America Market Value (US$ Million) Analysis by Cancer Type, 2017 to 2032
Figure 32: North America Market Value Share (%) and BPS Analysis by Cancer Type, 2022 to 2032
Figure 33: North America Market Y-o-Y Growth (%) Projections by Cancer Type, 2022 to 2032
Figure 34: North America Market Value (US$ Million) Analysis by Service Provider, 2017 to 2032
Figure 35: North America Market Value Share (%) and BPS Analysis by Service Provider, 2022 to 2032
Figure 36: North America Market Y-o-Y Growth (%) Projections by Service Provider, 2022 to 2032
Figure 37: North America Market Attractiveness by Test Type, 2022 to 2032
Figure 38: North America Market Attractiveness by Cancer Type, 2022 to 2032
Figure 39: North America Market Attractiveness by Service Provider, 2022 to 2032
Figure 40: North America Market Attractiveness by Country, 2022 to 2032
Figure 41: Latin America Market Value (US$ Million) by Test Type, 2022 to 2032
Figure 42: Latin America Market Value (US$ Million) by Cancer Type, 2022 to 2032
Figure 43: Latin America Market Value (US$ Million) by Service Provider, 2022 to 2032
Figure 44: Latin America Market Value (US$ Million) by Country, 2022 to 2032
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 48: Latin America Market Value (US$ Million) Analysis by Test Type, 2017 to 2032
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Test Type, 2022 to 2032
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Test Type, 2022 to 2032
Figure 51: Latin America Market Value (US$ Million) Analysis by Cancer Type, 2017 to 2032
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Cancer Type, 2022 to 2032
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Cancer Type, 2022 to 2032
Figure 54: Latin America Market Value (US$ Million) Analysis by Service Provider, 2017 to 2032
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Service Provider, 2022 to 2032
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Service Provider, 2022 to 2032
Figure 57: Latin America Market Attractiveness by Test Type, 2022 to 2032
Figure 58: Latin America Market Attractiveness by Cancer Type, 2022 to 2032
Figure 59: Latin America Market Attractiveness by Service Provider, 2022 to 2032
Figure 60: Latin America Market Attractiveness by Country, 2022 to 2032
Figure 61: Europe Market Value (US$ Million) by Test Type, 2022 to 2032
Figure 62: Europe Market Value (US$ Million) by Cancer Type, 2022 to 2032
Figure 63: Europe Market Value (US$ Million) by Service Provider, 2022 to 2032
Figure 64: Europe Market Value (US$ Million) by Country, 2022 to 2032
Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 68: Europe Market Value (US$ Million) Analysis by Test Type, 2017 to 2032
Figure 69: Europe Market Value Share (%) and BPS Analysis by Test Type, 2022 to 2032
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Test Type, 2022 to 2032
Figure 71: Europe Market Value (US$ Million) Analysis by Cancer Type, 2017 to 2032
Figure 72: Europe Market Value Share (%) and BPS Analysis by Cancer Type, 2022 to 2032
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Cancer Type, 2022 to 2032
Figure 74: Europe Market Value (US$ Million) Analysis by Service Provider, 2017 to 2032
Figure 75: Europe Market Value Share (%) and BPS Analysis by Service Provider, 2022 to 2032
Figure 76: Europe Market Y-o-Y Growth (%) Projections by Service Provider, 2022 to 2032
Figure 77: Europe Market Attractiveness by Test Type, 2022 to 2032
Figure 78: Europe Market Attractiveness by Cancer Type, 2022 to 2032
Figure 79: Europe Market Attractiveness by Service Provider, 2022 to 2032
Figure 80: Europe Market Attractiveness by Country, 2022 to 2032
Figure 81: Asia Pacific Market Value (US$ Million) by Test Type, 2022 to 2032
Figure 82: Asia Pacific Market Value (US$ Million) by Cancer Type, 2022 to 2032
Figure 83: Asia Pacific Market Value (US$ Million) by Service Provider, 2022 to 2032
Figure 84: Asia Pacific Market Value (US$ Million) by Country, 2022 to 2032
Figure 85: Asia Pacific Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 86: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 87: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 88: Asia Pacific Market Value (US$ Million) Analysis by Test Type, 2017 to 2032
Figure 89: Asia Pacific Market Value Share (%) and BPS Analysis by Test Type, 2022 to 2032
Figure 90: Asia Pacific Market Y-o-Y Growth (%) Projections by Test Type, 2022 to 2032
Figure 91: Asia Pacific Market Value (US$ Million) Analysis by Cancer Type, 2017 to 2032
Figure 92: Asia Pacific Market Value Share (%) and BPS Analysis by Cancer Type, 2022 to 2032
Figure 93: Asia Pacific Market Y-o-Y Growth (%) Projections by Cancer Type, 2022 to 2032
Figure 94: Asia Pacific Market Value (US$ Million) Analysis by Service Provider, 2017 to 2032
Figure 95: Asia Pacific Market Value Share (%) and BPS Analysis by Service Provider, 2022 to 2032
Figure 96: Asia Pacific Market Y-o-Y Growth (%) Projections by Service Provider, 2022 to 2032
Figure 97: Asia Pacific Market Attractiveness by Test Type, 2022 to 2032
Figure 98: Asia Pacific Market Attractiveness by Cancer Type, 2022 to 2032
Figure 99: Asia Pacific Market Attractiveness by Service Provider, 2022 to 2032
Figure 100: Asia Pacific Market Attractiveness by Country, 2022 to 2032
Figure 101: MEA Market Value (US$ Million) by Test Type, 2022 to 2032
Figure 102: MEA Market Value (US$ Million) by Cancer Type, 2022 to 2032
Figure 103: MEA Market Value (US$ Million) by Service Provider, 2022 to 2032
Figure 104: MEA Market Value (US$ Million) by Country, 2022 to 2032
Figure 105: MEA Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 106: MEA Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 107: MEA Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 108: MEA Market Value (US$ Million) Analysis by Test Type, 2017 to 2032
Figure 109: MEA Market Value Share (%) and BPS Analysis by Test Type, 2022 to 2032
Figure 110: MEA Market Y-o-Y Growth (%) Projections by Test Type, 2022 to 2032
Figure 111: MEA Market Value (US$ Million) Analysis by Cancer Type, 2017 to 2032
Figure 112: MEA Market Value Share (%) and BPS Analysis by Cancer Type, 2022 to 2032
Figure 113: MEA Market Y-o-Y Growth (%) Projections by Cancer Type, 2022 to 2032
Figure 114: MEA Market Value (US$ Million) Analysis by Service Provider, 2017 to 2032
Figure 115: MEA Market Value Share (%) and BPS Analysis by Service Provider, 2022 to 2032
Figure 116: MEA Market Y-o-Y Growth (%) Projections by Service Provider, 2022 to 2032
Figure 117: MEA Market Attractiveness by Test Type, 2022 to 2032
Figure 118: MEA Market Attractiveness by Cancer Type, 2022 to 2032
Figure 119: MEA Market Attractiveness by Service Provider, 2022 to 2032
Figure 120: MEA Market Attractiveness by Country, 2022 to 2032
